NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, has announced that a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo (DRC). The company has received regulatory approval from the local agency ACOREP to initiate the trial and has appointed Professor Patrick Katoto as principal investigator. Preparatory work, including staff training, is underway, and the NV-387 drug product is already available in the DRC, with first patient dosing anticipated within a few weeks, barring outbreak-related impediments.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. According to NanoViricides, oral delivery could offer significant advantages in resource-limited outbreak settings compared with treatments requiring infusions. This is particularly relevant in the DRC, where healthcare infrastructure may be constrained, and oral administration can simplify logistics and improve patient compliance.
The company has appointed Om Sai Clinical Research Private Limited as the contract research organization (CRO) for the Phase II trial, which will also serve as the CRO for the planned Phase II trial of NV-387 Oral Gummies for the treatment of Mpox in the DRC. This dual role underscores the potential of NV-387 as a versatile antiviral candidate.
The initiation of this trial comes at a critical time, as Ebola outbreaks continue to pose significant public health threats in Africa. The current outbreak in the DRC, caused by the Bundibugyo strain, has highlighted the need for effective and accessible treatments. NanoViricides' focus on an oral formulation could be a game-changer in outbreak response, enabling faster deployment and easier administration in remote areas.
NanoViricides' lead drug candidate, NV-387, is also being developed for other viral infections, including RSV, COVID-19, Influenza, and Mpox. The company's broad-spectrum approach aims to address multiple viral threats with a single platform, potentially reducing development timelines and costs. The company's technology is based on proprietary nanomedicine, which uses specially designed nanomaterials to target viruses directly.
The approval from ACOREP marks a significant regulatory milestone for NanoViricides, demonstrating progress in its clinical development pipeline. The company's ability to navigate regulatory processes in the DRC and secure a reputable principal investigator like Professor Katoto adds credibility to its efforts. As the trial moves forward, the outcomes could have far-reaching implications for Ebola treatment protocols and for the broader field of antiviral therapy.
Given the ongoing global health concerns, the success of this trial could pave the way for new treatment options that are more practical and scalable in outbreak settings. NanoViricides' commitment to developing oral antivirals aligns with global health priorities to improve pandemic preparedness and response.
